Anteris is a development-stage structural heart company focused entirely on the DurAVR Transcatheter Heart Valve (THV) System, a next-generation device designed to treat aortic stenosis via catheter-based delivery rather than open-heart surgery. What distinguishes DurAVR from existing TAVR devices is its single-piece biomimetic design: the valve is molded from a single piece of bovine pericardial tissue treated with Anteris' proprietary ADAPT anti-calcification technology, intended to replicate the geometry and blood flow of a healthy human aortic valve. Anteris argues this design delivers superior hemodynamics, lower calcification risk, and greater long-term durability versus the current standard of care. The DurAVR system also includes the ComASUR delivery system, which gives physicians precise rotational control during implantation. Anteris has no commercial revenue and funds operations through equity raises, including a combined ~$320M raised in January 2026 from a public offering and a private placement with Medtronic, which also acquired a strategic equity stake and collaboration rights. The path to commercialization runs through the PARADIGM Trial, a pivotal randomized study initiated in October 2025 that Anteris must complete to support FDA and CE Mark approval. Beyond DurAVR, Anteris holds a minority stake in v2vmedtech, an early-stage company developing a repair device for leaky mitral and tricuspid valves, but this is not a near-term revenue driver.